NasdaqGS - Nasdaq Real Time Price ? USD AstraZeneca PLC (AZN) Follow Compare 63.90 +0.70 (+1.11%) As of 1:44 PM EST. Market Open. All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Are You a Value Investor? This 1 Stock Could Be the Perfect Pick The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. Zacks ? 4 hours ago AZN +1.11% We Think AstraZeneca's (LON:AZN) Healthy Earnings Might Be Conservative The market seemed underwhelmed by last week's earnings announcement from AstraZeneca PLC ( LON:AZN ) despite the... Simply Wall St. ? 5 hours ago AZN +1.11% AZNCF 3 Growth Stocks Trading Near Their 52-Week Lows to Buy Right Now There are plenty of growth stocks trading at obscenely high valuations right now. If you're on the hunt for some deals and are willing to be patient, three overlooked stocks you should consider loading up on right now are AstraZeneca (NASDAQ: AZN), United Parcel Service (NYSE: UPS), and Dollar Tree (NASDAQ: DLTR). Shares of AstraZeneca finished last week just a few dollars away from the stock's 52-week low of $60.47. Motley Fool ? 8 hours ago UPS DLTR AZN +1.11% AstraZeneca upgraded to Neutral from Sell at UBS UBS upgraded AstraZeneca (AZN) to Neutral from Sell with an unchanged price target of 11,300 GBp. The firm cites the stock’s 24% decline over the past three months amid China government investigations and “disappointing” data on Dato-DXd lung potential for the upgrade. While significant China uncertainty, but wholesale loss of AstraZeneca’s franchise seems unlikely, the analyst tells investors in a research note. Published first on TheFly – the ultimate source for real-time, market-moving breaki TipRanks ? 9 hours ago AZN +1.11% AZNCF AstraZeneca price target lowered to EUR 140 from EUR 150 at Berenberg Berenberg lowered the firm’s price target on AstraZeneca (AZN) to EUR 140 from EUR 150 and keeps a Buy rating on the shares. Within the space of a year, AstraZeneca’s share price has given up all of its gains following further disappointment in Dato-DXd lung cancer data and elevated investor fears regarding employee investigations in China, the analyst tells investors in a research note. However, the firm says the company’s pipeline prospects are largely unchanged and the China impact appears to TipRanks ? 9 hours ago AZN +1.11% AZNCF AstraZeneca awards $3.5M for projects to improve access to healthcare for patients across the US WILMINGTON, Del., November 20, 2024--AstraZeneca today pledged $3.5 million to nonprofit organizations across the US as part of Accelerate Change Together (ACT) on Health Equity, an initiative to improve access, affordability and outcomes for patients in urban, suburban and rural communities. This brings the total contributions from the program to more than $15 million to date. Business Wire ? yesterday AZN +1.11% AZNCF Daiichi Sankyo and AstraZeneca’s Enhertu snubbed by UK’s NICE for third time Charity Breast Cancer Now has described the failure to negotiate a fair price of Enhertu as “utterly heartbreaking”. Pharmaceutical Technology ? yesterday 4568.T AZN +1.11% GLDAF AstraZeneca Is No Longer a Sell for Any Analyst as UBS Upgrades (Bloomberg) -- AstraZeneca Plc’s recent share-price rout has gone so far that the pharma stock has shaken off the last of its bearish analyst ratings.Most Read from BloombergParis to Replace Parking Spaces With TreesTrump Promises Could Have Seismic Impact on Washington EconomyNew York’s Transit Agency Approves $9 Congestion TollTokyo’s Scorching Summers Focus Public Anger Against Tree CuttingNY Congestion Pricing Survived a Pause. Here’s What Could Kill ItShares in the London-listed drug maker Bloomberg ? yesterday AZN +1.11% FTSE 100 and European-listed stocks to own in 2025, according to Barclays While there is more uncertainty for markets ahead, Barclays' analysts still highlight a number of stocks in which they see value in owning next year. Yahoo Finance UK ? yesterday BABWF ICAGY ^GSPC CHMP Endorses AstraZeneca's Tagrisso for Expanded Use in NSCLC The CHMP's opinion is based on late-stage data, which show that treatment with AZN's Tagrisso extends progression-free survival by more than three years in certain NSCLC patients. Zacks ? 2 days ago AZN +1.11% SPRO CSTL AstraZeneca’s Tagrisso recommended for approval in EU by CHMP for certain NSCLC AstraZeneca’s (AZN) Tagrisso has been recommended for approval in the European Union for the treatment of adult patients with locally advanced, unresectable non-small cell lung cancer, or NSCLC, whose tumors have epidermal growth factor receptor exon 19 deletions or exon 21 substitution mutations and whose disease has not progressed during or following platinum-based chemoradiation therapy, or CRT, the company announced. Published first on TheFly – the ultimate source for real-time, market-movin TipRanks ? 2 days ago AZN +1.11% AZNCF CHMP recommends AstraZeneca’s Tagrisso for EU approval for NSCLC CHMP's positive opinion was influenced by outcomes from the Phase III LAURA study. Pharmaceutical Technology ? 2 days ago AZN +1.11% GRAIL Announces First Patient Tested With Blood-Based Assay in Global Phase 3 Adjuvant Lung Cancer Study GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that the first patient has been tested for eligibility with the investigational GRAIL Non-Small Cell Lung Cancer (NSCLC) ctDNA Assay in the global TROPION-Lung12 Phase 3 study evaluating adjuvant treatment regimens in patients with Stage I adenocarcinoma NSCLC. The study is sponsored by AstraZeneca (LSE/STO/Nasdaq:AZN) in collaboration with Daiichi Sankyo (TSE: 4568). PR Newswire ? 2 days ago DSKYF DSNKY GRAL AstraZeneca picks first Treg cell therapy from Quell Therapeutics partnership AstraZeneca will advance preclinical and clinical development of the type 1 diabetes cell therapy candidate. Pharmaceutical Technology ? 3 days ago AZN +1.11% Astrazeneca (AZN) is a Top-Ranked Growth Stock: Should You Buy? Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. Zacks ? 3 days ago AZN +1.11% Is AstraZeneca PLC (AZN) the Best Immunotherapy Stock to Buy Now? We recently compiled a list of the 10 Best Immunotherapy Stocks to Buy Now. In this article, we are going to take a look at where AstraZeneca PLC (NASDAQ:AZN) stands against the other immunotherapy stocks. The global immunotherapy drugs market is rapidly expanding, with projections to grow from $240 billion in 2023 to $1.3 trillion by […] Insider Monkey ? 3 days ago AZN +1.11% Is AstraZeneca PLC (AZN)?A Cheap NASDAQ Stock To Invest In Now? We recently published a list of 10 Cheap NASDAQ Stocks To Invest In Now. In this article, we are going to take a look at where AstraZeneca PLC (NASDAQ:AZN) stands against other cheap NASDAQ stocks to invest in now. How Did The Stock Market Perform In Q3 2024? The stock market has been following an […] Insider Monkey ? 3 days ago AZN +1.11% How analysts are reacting to RFK Jr. as Trump's HHS pick President-elect Donald Trump has selected Robert F. Kennedy Jr. for the position of Secretary of Health & Human Services (HHS). The appointment has drawn significant attention due to Kennedy Jr.'s controversial stance on vaccines, including his designation as one of the "Disinformation Dozen" during the COVID-19 pandemic. Following the announcement, vaccine-related stocks experienced a notable decline. Yahoo Finance Senior Health Reporter Anjalee Khemlani analyzes the implications of this appointment and shares reactions from market analysts regarding its potential impact on the healthcare sector. To watch more expert insights and analysis on the latest market action, check out more Market Domination here. This post was written by Angel Smith Yahoo Finance Video ? 5 days ago MRNA +3.52% SNY +0.46% SNYNF Pharma Stock Roundup: AZN, BAYRY's Earnings, ABBV's Pipeline Setback AZN and BAYRY announce Q3 results. ABBV's studies on schizophrenia candidate, emraclidine, fail to meet goal. Zacks ? 5 days ago AZN +1.11% ABBV +2.59% BAYN.DE Stocks to Watch Friday: Applied Materials, Alibaba, Domino's, Novo Nordisk ↘? Applied Materials (AMAT): Shares fell 8% after the semiconductor-equipment company posted a weaker-than-expected sales outlook. ↘? Alibaba (BABA): The Chinese e-commerce company posted better-than-expected quarterly earnings, but disappointing revenue. The Wall Street Journal ? 6 days ago SNY +0.46% SNYNF AZN +1.11% Performance Overview Trailing total returns as of 11/21/2024, which may include dividends or other distributions. Benchmark is FTSE 100 Return AZN FTSE 100 YTD -3.07% +5.38% 1-Year +2.34% +8.71% 3-Year +20.45% +12.81%
